Clinical Trial Update: Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC [Phase 1, Phase 2]

View source ↗

Summary

An open-label phase 1b/2a trial evaluating Vactosertib in combination with Durvalumab for advanced/metastatic non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Vactosertib (Vactosertib)

Snippet

Sponsor: MedPacto, Inc. | Conditions: Non-Small Cell Lung Cancer Metastatic | Phase 1, Phase 2 | Status: COMPLETED